Document Detail

Micronucleus induction in the bone marrow of rats by pharmacological mechanisms. II: long-acting beta-2 agonism.
MedLine Citation:
PMID:  23408845     Owner:  NLM     Status:  In-Data-Review    
AZD9708 is a new chemical entity with selective and long-acting β2-agonistic properties currently being evaluated by AstraZeneca for potential use in treatment of respiratory diseases by the inhaled route. As part of the toxicological characterisation of this compound, an increased incidence of micronucleated immature erythrocytes (MIEs) was seen in the bone marrow of rats following single intravenous doses near the maximum tolerated. This effect was seen in the absence of in vitro genotoxicity in bacterial and mammalian cells and no consistent evidence of in vivo DNA damage in the the bone marrow or liver using the comet assay was observed. Because of the lack of signals for mutagenic potential, combined with the observation that MIE frequencies appeared to be increased in only some of the rats and the clearest response was seen at the intermediate dose, it was hypothesised that the effect was secondary to β2-adrenergic receptor overstimulation. Because it appears that this has not been previously described for β2-agonists and because pharmacodynamic/pharmacokinetic factors may influence the response, studies using repeated dosing were performed to investigate whether this would lead to compound-induced tachyphylaxis with tolerance induction and decreased responses indicated by β2-effect biomarkers. A series of experiments confirmed that a sequence of five escalating daily doses leading to systemic exposure corresponding to that after a single dose led to symptomatic tolerance, declining or diminished effects on plasma biomarkers of β2-effects (plasma glucose and potassium) and elimination of the micronucleus response. This suggests that the increased MIE frequencies after single doses of AZD9708 are secondary to physiological overstimulation of β2-adrenergic receptors, not a consequence of genotoxicity.
Ingrid Pontén; Peter Mutch; David J Nicholls; Alaa Saad; Cecilia Diaz Pohl; Alan Young; Charlotta Fred; Michael R O'Donovan; Per Aberg
Related Documents :
9331515 - The long-duration action of levodopa may be due to a postsynaptic effect.
2798525 - Heroin self-administration by rats: influence of dose and physical dependence.
20979935 - Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to contr...
8582955 - Cabergoline: a new drug for the treatment of hyperprolactinaemia.
10681375 - Metabolism and excretion of [(14)c]celecoxib in healthy male volunteers.
114635 - Quantitation of gold lymphocyte binding during chrysotherapy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Mutagenesis     Volume:  28     ISSN:  1464-3804     ISO Abbreviation:  Mutagenesis     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8707812     Medline TA:  Mutagenesis     Country:  England    
Other Details:
Languages:  eng     Pagination:  233-9     Citation Subset:  IM    
AstraZeneca R&D Södertälje, 151 85 Södertälje, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genetic damage in patients with chronic kidney disease, peritoneal dialysis and haemodialysis: a com...
Next Document:  Rv1894c is a novel hypoxia-induced nitronate monooxygenase required for Mycobacterium tuberculosis v...